PPI Therapy for Barrett's Esophagus

Introduction to PPI Therapy

The American Gastroenterological Association recommends long-term PPI therapy indefinitely for symptom control in patients with Barrett's esophagus, with standard once-daily dosing as the initial approach, escalating to twice-daily dosing only if symptoms persist or in patients with long-segment disease 1

PPIs are recommended primarily for controlling gastroesophageal reflux symptoms, not as chemopreventive agents, as stated by the American College of Gastroenterology 2, 3
The 2024 NICE guidelines explicitly state that high-dose PPIs showed no clinically important effect on all-cause mortality, progression to dysplasia, or cancer development in the AspECT trial, highlighting the need for ongoing surveillance 3
The American Gastroenterological Association recommends against discontinuing PPIs in Barrett's patients, as they may reduce progression risk to esophageal adenocarcinoma, despite lack of definitive chemoprevention evidence 1

The American College of Gastroenterology recommends starting with standard once-daily PPI dosing for symptom control, with the dose reviewed regularly to assess for side effects and prevent long-term complications including bone fractures, infections, and electrolyte disturbances 3, 1
Twice-daily PPI therapy should be considered for patients who don't respond clinically to once-daily therapy, as well as for patients with long-segment Barrett's esophagus (>3 cm circumferentially) who have particularly high nocturnal acid exposure 1

Regular endoscopic surveillance remains necessary for all Barrett's patients on PPI therapy to monitor for dysplasia development, as PPI therapy does not eliminate cancer risk or obviate the need for surveillance protocols, according to the American College of Gastroenterology 1
Monitor for potential long-term side effects including osteoporosis, gastrointestinal infections, and pneumonia, with high-dose PPIs not associated with increased adverse events or all-cause mortality in the AspECT trial 2, 3

Antireflux surgery (Nissen fundoplication) does not offer advantages over medical PPI therapy for preventing progression to dysplasia or cancer, and may be considered only for patients intolerant to PPIs or with concerns about long-term medication use, as stated by the Society of American Gastrointestinal and Endoscopic Surgeons 1
Aspirin should not be offered specifically for chemoprevention in Barrett's esophagus, as the AspECT trial showed insufficient evidence to recommend aspirin, and bleeding risks may outweigh potential benefits, according to the American Heart Association 3, 1

The British Society of Gastroenterology recommends optimizing PPI therapy to twice-daily dosing for better acid suppression in patients with Barrett's esophagus, which can help alleviate throat symptoms such as globus sensation and phlegm 4
Inadequate acid control allows gastric contents to reach the upper esophagus and throat, causing mucus production and throat irritation, and can be managed with intensive acid suppression 5
Elevating the head of the bed by 6-8 inches, avoiding eating within 3 hours of bedtime, and staying well-hydrated can help reduce nocturnal reflux and alleviate throat symptoms 4

The National Institute for Health and Care Excellence (NICE) guidelines confirm that high-dose PPIs do not prevent progression to dysplasia or cancer in Barrett's esophagus patients, making ongoing endoscopic surveillance essential 6, 7
PPIs are recommended for symptom control in Barrett's esophagus, not for cancer prevention, and patients should continue with regular surveillance endoscopy regardless of symptom control 6
The American Gastroenterological Association recommends that Barrett's esophagus surveillance schedule should not change based on current symptoms 8

Patients with Barrett's esophagus should seek urgent evaluation if they develop difficulty swallowing solid foods, unintentional weight loss, vomiting blood or black tarry stools, or severe chest pain 5

Initiate all Barrett’s esophagus patients on once‑daily PPI therapy for symptom control; regularly review dose for adverse effects such as bone fractures, infections, and electrolyte disturbances. [Guideline: Gastroenterology Society] 9
High‑dose PPI regimens do not provide a clinically important benefit in preventing progression to dysplasia or cancer, as demonstrated in the AspECT randomized trial. [Guideline: Gastroenterology Society] 10

The American Gastroenterological Association advises against strategies aimed at eliminating esophageal acid exposure (e.g., PPIs > once daily, pH‑guided titration, or antireflux surgery) when the goal is esophageal adenocarcinoma prevention. [Guideline: American Gastroenterological Association] 11
Antireflux surgery offers no superior cancer‑preventive effect compared with optimal medical GER‑D therapy in Barrett’s esophagus. [Guideline: American Gastroenterological Association] 12

For patients without dysplasia, perform four‑quadrant biopsies every 2 cm of Barrett’s segment using white‑light endoscopy. [Guideline: Gastroenterology Society] 11
For patients with known or suspected dysplasia, obtain four‑quadrant biopsies every 1 cm of the segment. [Guideline: Gastroenterology Society] 13
Surveillance intervals and techniques should remain unchanged regardless of symptom control or current medication regimen; follow established protocols based on dysplasia grade. [Guideline: Gastroenterology Society] 11